AR081026A1 - Analogos de quinolina y su uso en el tratamiento de enfermedades respiratorias - Google Patents

Analogos de quinolina y su uso en el tratamiento de enfermedades respiratorias

Info

Publication number
AR081026A1
AR081026A1 ARP110101593A ARP110101593A AR081026A1 AR 081026 A1 AR081026 A1 AR 081026A1 AR P110101593 A ARP110101593 A AR P110101593A AR P110101593 A ARP110101593 A AR P110101593A AR 081026 A1 AR081026 A1 AR 081026A1
Authority
AR
Argentina
Prior art keywords
het
alkyl
arylene
arilen
halo
Prior art date
Application number
ARP110101593A
Other languages
English (en)
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR081026A1 publication Critical patent/AR081026A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Su uso en el tratamiento de la inflamacion pulmonar o de la broncoconstriccion y composiciones que los comprenden y procesos para su preparacion. Reivindicacion 1: Un compuesto de Formula (1): donde X es un anillo de fenilo sustituido seleccionado entre: (2); Z es un enlace o una porcion seleccionada entre: (3); R1 es CH2OH, CH2CH2OH, N(H)C(O)H, o N(H)S(O2) alquilo C1-3, y R2 es H; o R1 y R2 junto con el fenilo al cual están unidos forman un anillo heterocíclico fusionado, bicíclico que tiene 9 o 10 átomos del anillo donde 1 o 2 átomos del anillo se seleccionan entre N, O y S, donde dicho anillo heterocíclico fusionado biciclico es opcionalmente sustituido con uno, dos o tres sustituyentes adicionales seleccionados independientemente entre alquilo, oxo y OH; R3 se selecciona entre alquileno C4-2, alquenileno C4-12, alquinileno C4-12, R8-O-R8, R8-N(R7)-R8, cicloalquileno C3-6, R8-cicloalquileno C3-6, R8-cicloalquilen C3-6-Het, cicloalquilen C3-6-R8, R8-cicloalquilen C3-6-R8, arileno C6-10, R8-arileno C6-10, arilen C6-10-R8, R8-arilen C6-10-R8, R8-arilen C6-10-O-R8, R8-arilen C6-10-N(R7)-R8, R8-arilen C6-10-ariIeno C6-10, Het, R8-Het, Het-R8, R8-Het-R8, R8-O-Het, R8-arilen C6-10-O-Het, R8-arilen C6-10-C(O)-Het, R8-arilen C6-10-N(R7)-Het, R8-Het-arileno C6-10, R8-arilen C6-10-Het, y R8-O-R8-arileno C6-10; donde dicho alquileno, alquenileno o alquinileno es cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados entre halo, oxo, y OR7; donde dichos grupos fenileno están cada uno opcionalmente sustituido con 1, 2, 3 o 4 sustituyentes seleccionados entre halo, alquilo, y OR7; Het es heterocicleno monocíclico, saturado o insaturado, de 5-6 miembros o un heterocicleno bicíclico, saturado o insaturado, de 8-10 miembros donde 1 o 2 átomos del anillo se seleccionan entre N, O y S, y donde dicho heterocicleno monocíclico o bicíclico está opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados entre halo, alquilo, alcoxi, oxo y OH; Y es C(O), OC(O), C(O)N(R7), C(O)N(R7)CH2, OC(O)NR7CH2, N(R7)C(O), o N(R7)C(O)N(R7); a es 0, 1, 2, 3, 4; R4 se selecciona entre halo, alquilo, y OR7; R5 es H o alquilo; b es 1, 2, 3, 4, o 5; R6 se selecciona entre halo, alquilo, haloalquilo, OR7, O-haloalquilo, R8-OR7, O-R8-OR7, C(O)alquilo, O-R8-C(O)alquilo, CON(R7)2, R8-CON(R7)2, R8-N(R7)2, N(R7)C(O)alquilo, N(R7)C(O)N(R7)2, N(R7)SO2alquilo, R8-SO2N(R7)2, y CN; o dos R6 en carbonos adyacentes, junto con el fenilo al cual están unidos forman un anillo heterocíclico bicíclico que tiene 9 o 10 átomos del anillo donde 1 o 2 átomos del anillo se seleccionan entre N, O y S; R7 es H o alquilo; y R8 es alquileno C1-10, alquenileno C2-10, o alquinileno C2-10 donde cada R8 es opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados entre halo, oxo, y OR7; con la condicion de que la cantidad total de átomos de carbono en las cadenas de alquileno C1-10, alquenileno C2-10, o alquinileno C2-10 de dos grupos R8 en cualquier definicion de R3 no sea superior a 12; R9 es H o alquilo C1-3; o su sal farmacéuticamente aceptable.
ARP110101593A 2010-05-10 2011-05-09 Analogos de quinolina y su uso en el tratamiento de enfermedades respiratorias AR081026A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33302010P 2010-05-10 2010-05-10
US40693010P 2010-10-26 2010-10-26
US201161477263P 2011-04-20 2011-04-20

Publications (1)

Publication Number Publication Date
AR081026A1 true AR081026A1 (es) 2012-05-30

Family

ID=44072535

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101593A AR081026A1 (es) 2010-05-10 2011-05-09 Analogos de quinolina y su uso en el tratamiento de enfermedades respiratorias

Country Status (9)

Country Link
US (2) US8394829B2 (es)
EP (1) EP2569285A1 (es)
JP (2) JP5807058B2 (es)
AR (1) AR081026A1 (es)
AU (1) AU2011253203A1 (es)
CA (1) CA2796826A1 (es)
NZ (1) NZ603136A (es)
UY (1) UY33372A (es)
WO (1) WO2011143105A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33372A (es) * 2010-05-10 2011-12-30 Gilead Sciences Inc ?análogos de quinolina bi?funcionales, su uso en la manufactura de medicamentos,composiciones que los comprenden y procesos de preparacion?.
MX2015010714A (es) 2013-02-19 2016-06-14 Pfizer Compuestos de azabencimidazol.
WO2015119998A1 (en) * 2014-02-06 2015-08-13 Abbvie, Inc. 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
JP6125467B2 (ja) * 2014-06-16 2017-05-10 富士フイルム株式会社 プリント注文受付機とその作動方法および作動プログラム
EP3172210B1 (en) 2014-07-24 2020-01-15 Pfizer Inc Pyrazolopyrimidine compounds
DK3177624T3 (da) 2014-08-06 2019-07-01 Pfizer Imidazopyridazinforbindelser
CA2972259A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN106554350B (zh) * 2015-09-29 2019-12-20 四川海思科制药有限公司 具有β2激动活性的苯并杂环衍生物及其制法和应用
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
CN112250557A (zh) * 2020-10-23 2021-01-22 徐州工程学院 一种高效合成1,6-二烯-3-酮衍生物的方法

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
US3885047A (en) 1972-06-16 1975-05-20 Mead Johnson & Co Ocular hypotensive process employing dextrorotatory phenethanolamines
US4145542A (en) 1974-06-13 1979-03-20 Otsuka Pharmaceutical Co., Ltd. 5- 1-Hydroxy-2-(heterocyclic-amino)!alkyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
US4761421A (en) 1985-05-08 1988-08-02 Merck & Co., Inc. Use of certain compounds in livestock food as growth promotants for better feed utilization and improved carcass composition
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
GB9107196D0 (en) 1991-04-05 1991-05-22 Sandoz Ag Improvements in or relating to organic compounds
EP0940154B1 (en) 1991-07-02 2007-04-18 Nektar Therapeutics Device for delivering aerosolized medicaments
PT1086688E (pt) 1991-12-18 2004-06-30 Minnesota Mining & Mfg Formulacoes de aerossol em suspensao
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5455252A (en) 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
JP3093271B2 (ja) 1993-07-02 2000-10-03 ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシャフト ミット ベシュレンクテル ハフツング フルオルアルコキシ置換のベンズアミド及び環状ヌクレオチドホスホジエステラーゼ阻害剤としてのその使用
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
RO119117B1 (ro) 1995-04-14 2004-04-30 Glaxo Wellcome Inc. Inhalator cu doză fixă pentru fluticazon propionat
US5728712A (en) 1995-05-19 1998-03-17 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
GB9523267D0 (en) 1995-11-14 1996-01-17 Sandoz Ltd Organic compounds
JP2000510866A (ja) 1996-05-20 2000-08-22 ダーウィン・ディスカバリー・リミテッド Ｔｎｆとｐｄｅ―ｉｖのインヒビターとしてのキノリンスルホンアミド
DE69738949D1 (de) 1996-05-20 2008-10-09 Darwin Discovery Ltd Chinolincarboxamide als tnf-inhibitoren und als pde-iv inhibitoren
GB9712761D0 (en) 1997-06-17 1997-08-20 Chiroscience Ltd Quinolines and their therapeutic use
US6069151A (en) 1996-11-06 2000-05-30 Darwin Discovery, Ltd. Quinolines and their therapeutic use
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
CN1314811A (zh) 1998-08-26 2001-09-26 史密丝克莱恩比彻姆公司 治疗肺病的方法
US6262070B1 (en) 1998-11-04 2001-07-17 Darwin Discovery Ltd. Heterocyclic compounds and their therapeutic use
US6329034B1 (en) 1999-01-18 2001-12-11 Roger L. Pendry Label having tab member and methods for forming, applying and using the same
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
PT1183061E (pt) 1999-06-05 2005-08-31 Innovata Biomed Ltd Sistema de administracao de medicamento
GB2353222B (en) 1999-06-23 2001-09-19 Cambridge Consultants Inhalers
EP2193808A1 (en) 1999-08-21 2010-06-09 Nycomed GmbH Synergistic combination
GB9920839D0 (en) 1999-09-04 1999-11-10 Innovata Biomed Ltd Inhaler
US6880555B1 (en) 1999-10-12 2005-04-19 Shl Medical Ab Inhaler
GB9928265D0 (en) 1999-12-01 2000-01-26 Innovata Biomed Ltd Inhaler
AU1225001A (en) 1999-12-08 2001-06-18 Qualcomm Incorporated Method and system for distributing advertisements to client devices
SE9904706D0 (sv) 1999-12-21 1999-12-21 Astra Ab An inhalation device
US6410563B1 (en) 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US7171965B2 (en) 2000-02-01 2007-02-06 Valois S.A.S. Breath actuated dry powder inhaler and tape dose strip
BR0111440A (pt) 2000-06-05 2003-06-03 Altana Pharma Ag Compostos eficazes como agonistas do (beta)2-adrenorreceptor bem como inibidores de pde4
FR2813593B1 (fr) 2000-09-07 2002-12-06 Valois Sa Dispositif de distribution de produit fluide de type multidose
GB0026647D0 (en) 2000-10-31 2000-12-13 Glaxo Group Ltd Medicament dispenser
US6740666B2 (en) 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
EP1404330B1 (en) 2001-06-27 2005-06-01 Merck Frosst Canada & Co. Substituted 8-arylquinoline pde4 inhibitors
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
CA2479069A1 (en) 2002-03-18 2003-09-25 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Hetero-bridge substituted 8-arylquinoline pde4 inhibitors
US6889690B2 (en) 2002-05-10 2005-05-10 Oriel Therapeutics, Inc. Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages
AU2003239880A1 (en) * 2002-05-28 2003-12-12 Theravance, Inc. ALKOXY ARYL Beta2 ADRENERGIC RECEPTOR AGONISTS
EP1517895B1 (en) 2002-06-25 2007-03-14 Merck Frosst Canada Ltd. 8-(biaryl) quinoline pde4 inhibitors
EP1592419A1 (en) 2002-11-22 2005-11-09 Merck Frosst Canada & Co. Use of phosphodiesterase-4 inhibitors as enhancers of cognition
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
EP1635829A1 (en) 2003-04-30 2006-03-22 Merck Frosst Canada Ltd. 8-(3-biaryl)phenylquinoline phosphodiesterase-4-inhibitors
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
EP1488819A1 (en) 2003-06-16 2004-12-22 Rijksuniversiteit te Groningen Dry powder inhaler and method for pulmonary inhalation of dry powder
US7064129B2 (en) 2003-08-18 2006-06-20 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
GB0322726D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
GB0322722D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
EP1833822A2 (en) 2004-08-16 2007-09-19 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
GB0503955D0 (en) 2005-02-25 2005-04-06 Glaxo Group Ltd Novel compounds
CA2617286A1 (en) * 2005-08-01 2007-02-08 Chiesi Farmaceutici S.P.A. Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US20100004215A1 (en) 2005-10-19 2010-01-07 Abhijit Ray Compositions of phosphodiesterase type iv inhibitors
RU2464973C2 (ru) 2006-01-24 2012-10-27 НексБио, Инк. Технология изготовления макромолекулярных микросфер
JP2009118740A (ja) 2006-03-03 2009-06-04 Ajinomoto Co Inc Ｌ−アミノ酸の製造法
GB0605462D0 (en) 2006-03-17 2006-04-26 Glaxo Group Ltd Novel compounds
JP2009530364A (ja) * 2006-03-20 2009-08-27 ファイザー・リミテッド アミン誘導体
WO2007146869A1 (en) 2006-06-09 2007-12-21 Parion Sciences, Inc. Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity
BRPI0713253A2 (pt) 2006-07-07 2012-10-30 Steven P Govek método de inibição de pde4, método de tratamento de um doença mediada por pde4, composto e composição farmacêutica
WO2009015286A2 (en) 2007-07-24 2009-01-29 Nexbio, Inc. Technology for the preparation of microparticles
WO2009100169A1 (en) 2008-02-06 2009-08-13 Glaxo Group Limited Dual pharmacophores - pde4-muscarinic antagonistics
WO2009142589A1 (en) 2008-05-20 2009-11-26 Astrazeneca Ab Combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
US8263623B2 (en) * 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
WO2010015792A1 (en) * 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
UY32521A (es) 2009-04-03 2010-10-29 Astrazeneca Ab Combinación para emplear en el tratamiento de enfermedades respiratorias
AR081377A1 (es) * 2010-05-10 2012-08-29 Gilead Sciences Inc Compuestos de pirazolopiridina bifuncionales
UY33372A (es) * 2010-05-10 2011-12-30 Gilead Sciences Inc ?análogos de quinolina bi?funcionales, su uso en la manufactura de medicamentos,composiciones que los comprenden y procesos de preparacion?.

Also Published As

Publication number Publication date
AU2011253203A1 (en) 2012-11-22
US8394829B2 (en) 2013-03-12
JP5807058B2 (ja) 2015-11-10
UY33372A (es) 2011-12-30
WO2011143105A1 (en) 2011-11-17
US20130012504A1 (en) 2013-01-10
JP2015131833A (ja) 2015-07-23
JP2013526520A (ja) 2013-06-24
NZ603136A (en) 2014-11-28
CA2796826A1 (en) 2011-11-17
EP2569285A1 (en) 2013-03-20
US20110275622A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
AR081026A1 (es) Analogos de quinolina y su uso en el tratamiento de enfermedades respiratorias
AR092959A1 (es) Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR105648A1 (es) Métodos para la preparación de ácidos biliares y derivados de los mismos
UY33961A (es) Compuestos de bis(fuoroalquil)-1,4-benziodiazepinona
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
ECSP14004812A (es) Triazolopiridinas sustituidas
AR081377A1 (es) Compuestos de pirazolopiridina bifuncionales
AR103251A1 (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
AR094668A1 (es) Amidas como moduladores de canales de sodio
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR095326A1 (es) Heterociclos tricíclicos como inhibidores de la proteína bet
MY184433A (en) 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
AR100073A1 (es) Sulfonas heterocíclicas sustituidas con heteroarilos
CO6660438A2 (es) Método para producir una preparación de inmunoglobina con rendimiento mejorado
PE20190515A1 (es) Peptidos modificados de auristatina y conjugados anticuerpo-farmaco de los mismos
AR088801A1 (es) Compuestos inhibidores de la fosfodiesterasa del tipo 10a
AR088535A1 (es) Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1)
AR063119A1 (es) Derivados de piridinonas sustituidas, composiciones farmaceuticas que los contienen y usos como antagonistas en trastornos asociados a receptores del tipo i de la hormona de melanina(mch-1 o mchr-1)
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
UY35293A (es) Isotiazoles sustituidos con amino
AR097325A1 (es) Pirroles anillados
AR084857A1 (es) Derivados de azetidina utiles para el tratamiento de enfermedades metabolicas e inflamatorias
AR094553A1 (es) Formas de oxadiazolpirazina
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR094496A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas

Legal Events

Date Code Title Description
FB Suspension of granting procedure